Quick answer
What do the murine colitis studies report about KPV? Three groups report that KPV, given in drinking water or loaded into nanoparticle-hydrogel systems, was associated with reduced inflammatory readouts in mouse DSS, TNBS and CD45RBhi transfer colitis. The models differ in mechanism, so findings are narrow; they are mouse data only. For laboratory research use only.
Mouse colitis is the best-known animal setting for KPV, and the reason is practical: intestinal epithelium is where α-MSH-derived peptides and the PepT1 transporter meet. Searching for KPV murine colitis models usually leads to a handful of papers that use different disease-induction methods, which are easy to blur together. This article separates them. It describes each model, what KPV was reported to do in it, and what a reader needs to check before comparing studies. For laboratory research use only; not for human consumption.
The molecule is introduced in what is KPV and the KPV research overview. The practical details of vehicles and routes are in the companion article on published study parameters; this one is about the models themselves. The KPV research vials page lists the supplied form (5 mg and 10 mg lyophilized vials, ≥98% HPLC purity).
Three induction methods, three different diseases
A mouse does not get colitis in one way. The KPV literature uses three approaches, each with a different mechanism and a different timescale.
| Model | How it is induced | Used with KPV in |
|---|---|---|
| DSS colitis | Dextran sodium sulfate given to the animals, producing acute (or, with repeated cycles, chronic) colitis [4] | [1, 2, 7] |
| TNBS colitis | 2,4,6-trinitrobenzene sulfonic acid, a hapten agent described alongside oxazolone and DSS in protocol work [4] | [1] |
| CD45RBhi T-cell transfer colitis | Transfer of the CD45RBhi subset of CD4+ T cells into immunodeficient scid mice, which develop inflammatory bowel disease; co-transfer of the CD45RBlo subset prevents it [3] | [2] |
The chemical models act on the epithelium or provoke local immune responses; the transfer model depends on T-cell function, which is a different mechanism. A reviewer of murine models notes that the interpretation of colitis depends on mucosal immunology, genetic and immunologic defects in the mice, and the intestinal microbiome [5]. A result in one model therefore supports a narrow statement, not a general one.
What KPV was reported to do in each model
DSS and TNBS (drinking water). KPV added to the drinking water reduced the incidence of colitis in both models, with decreases in histologic inflammation and in pro-inflammatory cytokine mRNA [1]. The paper also reported that PepT1, a transporter expressed in intestinal epithelium and immune cells, mediates KPV uptake in cultured cells, offering a mechanism for entry.
DSS and transfer colitis, plus an MC1R-deficient strain. A second group reported that, in DSS colitis, mice receiving KPV showed earlier recovery and stronger regain of body weight, with fewer inflammatory infiltrates and lower myeloperoxidase (MPO) activity in colonic tissue. In the transfer model, KPV was associated with recovery, regained body weight and reduced histologic inflammation. In mice with a nonfunctional melanocortin-1 receptor, all animals in the KPV group survived DSS colitis, which the authors read as an effect at least partly independent of MC1R signaling [2].
DSS with a targeted delivery system. A third group delivered KPV in nanoparticles within an alginate–chitosan hydrogel. Mice given DSS followed by that preparation were protected on inflammatory and histologic measures, and the authors state that KPV delivered this way was effective at a concentration 12,000-fold lower than in free solution [7].
Why PepT1 expression matters for the model
PepT1 is normally strongest in the small intestine and absent from the colon. In colonic tissue from donors with chronic ulcerative colitis or Crohn's disease, hPepT1 expression was reported to occur aberrantly, whereas normal colon and microscopic colitis tissue lacked it [6]. The transporter accepts essentially every di- and tripeptide but not longer peptides [8], and KPV is a tripeptide. Together these points explain why colonic inflammation was chosen as a setting for KPV uptake: inflamed colon is where the transporter would be present to carry the peptide into cells. It also implies a caveat. If PepT1 is induced by the inflammation, uptake in a healthy colon would be expected to be lower, and a result in a diseased model cannot be extended to normal tissue without a direct test.
Endpoints: what each one measures
| Endpoint | What it reports | Weakness to remember |
|---|---|---|
| Body-weight change | Overall course of disease | Affected by food and water intake, including drinking-water delivery of a test substance |
| Histologic score | Tissue damage and infiltrate | Scorer subjectivity; blinding is needed |
| MPO activity | Neutrophil content of tissue | One cell type only |
| Cytokine mRNA | Inflammatory gene expression | mRNA does not equal secreted protein |
| Survival | Severe outcomes | Dependent on model severity and ethical endpoints |
The point about drinking-water delivery deserves emphasis. DSS itself is delivered in drinking water, and so is KPV in the first study; if animals drink less, both exposures and body weight change, so water intake should be recorded.
Variables that change the outcome of any colitis model
- Strain and sex. Susceptibility to chemically induced colitis varies by strain, and the protocol literature describes models for acute and chronic forms separately [4].
- Microbiome and housing. The review of murine models emphasizes the microbiome as an influence on inflammation [5], so cage effects and vendor can confound comparisons.
- Timing relative to induction. A peptide given before, during or after the inducing agent tests different questions: protection, modification or recovery.
- Vehicle and delivery. Free solution and nanoparticle-in-hydrogel preparations are different test articles [7].
- Peptide identity and purity. Confirm against batch documentation; see KPV purity testing, how to read a COA and the COA page.
Reading across the three groups
Taken together, the three groups report a consistent direction in three different induction models: KPV was associated with reduced inflammatory readouts. That consistency across DSS, TNBS and T-cell transfer is the main strength of the literature, because the three differ in mechanism. Its weaknesses are equally clear. Most of the work comes from a small number of groups, the species is always the mouse, the abstracts do not support quantitative comparison across studies, and the delivery methods differ. Nothing in it addresses intact human tissue or any outcome outside the model.
Concentration arithmetic for any solution made in a lab is a formula: peptide mass divided by diluent volume. Use the reconstitution calculator rather than a rule of thumb, and record the figures. If a lab intends to compare its results with the cited work, matching the induction agent, strain, endpoints and delivery format matters more than matching the peptide mass.
Reporting standards that make colitis data comparable
Because the abstracts leave many parameters unstated, a new study adds value mainly by stating them. A minimal reporting list for a colitis experiment includes: the induction agent and its concentration or amount, the strain, sex and age of the mice, the vendor and the housing conditions, the number of animals per group and how they were allocated, the timing of every intervention relative to induction, the exact composition of the test article, the vehicle, the primary endpoint declared in advance, and whether histology was scored blind. Each item is a variable that the protocol literature and model reviews identify as capable of shifting results [4, 5].
Two further habits help. First, report animals removed from analysis and the reason, because severe colitis often forces early endpoints that bias survivors. Second, report the raw numbers behind percentage changes, so that a reader can recompute them. Where a peptide solution was made in the lab, give the calculation from vial mass and diluent volume as well as the final concentration; the reconstitution calculator and the article peptide reconstitution volume calculations explain the arithmetic. These details cost little to record and make the difference between a result that can be built on and one that can only be quoted.
How the colitis work connects to the rest of the KPV literature
The colitis models connect to cell-culture work through NF-κB. In epithelial and immune cells, KPV was reported to reduce NF-κB and MAP kinase signaling, which predicts lower cytokine production, the same direction seen in the tissue [1]. The cell-level evidence is discussed in the articles on KPV and NF-κB and on inflammation model readouts. For the parent hormone and receptor-based mechanisms, see KPV vs α-MSH, and for the four-component blend that contains KPV, see KLOW Stack research guide and KLOW Stack product page.
Frequently asked questions
Which mouse colitis models have been used with KPV?
DSS colitis, TNBS colitis and CD45RBhi T-cell transfer colitis.
How was KPV given in the first colitis study?
It was added to the drinking water of the mice, according to the abstract.
What did KPV do in the DSS model?
Published abstracts report earlier recovery of body weight, fewer inflammatory infiltrates, lower MPO activity and reduced cytokine mRNA expression.
Did the effect depend on the melanocortin-1 receptor?
In mice with a nonfunctional MC1R, all animals in the KPV group survived DSS colitis, which the authors read as an effect at least partly independent of that receptor.
Why is PepT1 relevant?
Cell work reported that KPV enters cells through PepT1, and hPepT1 expression was reported to occur aberrantly in inflamed colon but not normal colon.
What is MPO activity?
Myeloperoxidase activity in colonic tissue, used as a marker of neutrophil infiltration.
Is DSS colitis the same as transfer colitis?
No. DSS is chemically induced; transfer colitis depends on transferred CD4 T cells in immunodeficient mice.
What did the nanoparticle study report?
KPV in nanoparticles within a polysaccharide hydrogel protected mice from DSS colitis at a concentration 12,000-fold lower than free KPV.
Do these studies apply to people?
They are mouse studies and do not establish anything outside the models.
What controls matter most in a colitis experiment?
Vehicle controls, an uninduced group, recorded water intake, blinded histology and matched strain, sex and housing.
Related reading: KPV Nanoparticle Delivery Systems: A Research Review, KPV and NF-κB Signaling: Evidence by Pathway Step, KPV and the PepT1 Transporter: Uptake Evidence.
References
- Dalmasso G, Charrier–Hisamuddin L, Thu Nguyen HT, Yan Y, Sitaraman S, Merlin D. PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal Inflammation. Gastroenterology. 2008;134(1):166-178. doi:10.1053/j.gastro.2007.10.026
- Kannengiesser K, Maaser C, Heidemann J, Luegering A, Ross M, Brzoska T, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflammatory Bowel Diseases. 2008;14(3):324-331. doi:10.1002/ibd.20334
- Powrie F, Leach MW, Mauze S, Menon S, Barcomb Caddle L, Coffman RL. Inhibition of Thl responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4+ T cells. Immunity. 1994;1(7):553-562. doi:10.1016/1074-7613(94)90045-0
- Wirtz S, Popp V, Kindermann M, Gerlach K, Weigmann B, Fichtner-Feigl S, et al. Chemically induced mouse models of acute and chronic intestinal inflammation. Nat Protoc. 2017;12(7):1295-1309. doi:10.1038/nprot.2017.044
- Kiesler P, Fuss IJ, Strober W. Experimental Models of Inflammatory Bowel Diseases. Cellular and Molecular Gastroenterology and Hepatology. 2015;1(2):154-170. doi:10.1016/j.jcmgh.2015.01.006
- Merlin D, Si-Tahar M, Sitaraman SV, Eastburn K, Williams I, Liu X, et al. Colonic epithelial hPepT1 expression occurs in inflammatory bowel disease: Transport of bacterial peptides influences expression of MHC class 1 molecules. Gastroenterology. 2001;120(7):1666-1679. doi:10.1053/gast.2001.24845
- Laroui H, Dalmasso G, Nguyen HTT, Yan Y, Sitaraman SV, Merlin D. Drug-Loaded Nanoparticles Targeted to the Colon With Polysaccharide Hydrogel Reduce Colitis in a Mouse Model. Gastroenterology. 2010;138(3):843-853.e2. doi:10.1053/j.gastro.2009.11.003
- Daniel H. Molecular and Integrative Physiology of Intestinal Peptide Transport. Annu. Rev. Physiol.. 2004;66(1):361-384. doi:10.1146/annurev.physiol.66.032102.144149
